Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Karunathilake, Kanchana
TRIDENT, NCT02699645 / 2016-003724-23: Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial	Recruiting	3	1600	Europe, RoW	telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg, Triple Pill, Placebo	The George Institute, The University of New South Wales	Intracerebral Haemorrhage (ICH), Hypertension	06/25	06/25